Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update

Alok A. Khorana, Marc Shapiro, Pamela B. Mangu, Jordan Berlin, Anitra Engebretson, Theodore S. Hong, Anirban Maitra, Matthew H.G. Katz, Supriya G. Mohile, Matthew Mumber, Richard Schulick, Susan Urba, Herbert J. Zeh

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Purpose To update the Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31, 2016. The October 2016 update focuses solely on new evidence that pertains to clinical question 4 of the guideline: What is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumor? Methods The recently published results of a randomized phase III study prompted an update of this guideline. The high quality of the reported evidence and the potential for its clinical impact prompted the Expert Panel to revise one of the guideline recommendations. Results The ESPAC-4 study, a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy compared gemcitabine and capecitabine with gemcitabine monotherapy in 730 evaluable patients with resected pancreatic ductal adenocarcinoma. Median overall survival was improved in the doublet arm to 28.0 months (95% CI, 23.5 to 31.5 months) versus 25.5 months (95% CI, 22.7 to 27.9 months) for gemcitabine alone (hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = .032). Grade 3 and 4 adverse events were similar in both arms, although higher rates of hand-foot syndrome and diarrhea occurred in patients randomly assigned to the doublet arm. Recommendations All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications. The doublet regimen of gemcitabine and capecitabine is preferred in the absence of concerns for toxicity or tolerance; alternatively, monotherapy with gemcitabine or fluorouracil plus folinic acid can be offered. Adjuvant treatment should be initiated within 8 weeks of surgical resection, assuming complete recovery. The remaining recommendations from the original 2016 ASCO guideline are unchanged.

Original languageEnglish (US)
Pages (from-to)2324-2328
Number of pages5
JournalJournal of Clinical Oncology
Volume35
Issue number20
DOIs
StatePublished - Jul 10 2017
Externally publishedYes

Fingerprint

gemcitabine
Medical Oncology
Pancreatic Neoplasms
Practice Guidelines
Guidelines
Adjuvant Chemotherapy
Hand-Foot Syndrome
Leucovorin
Combination Drug Therapy
Fluorouracil
Multicenter Studies
Diarrhea
Adenocarcinoma
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Potentially curable pancreatic cancer : American society of clinical oncology clinical practice guideline update. / Khorana, Alok A.; Shapiro, Marc; Mangu, Pamela B.; Berlin, Jordan; Engebretson, Anitra; Hong, Theodore S.; Maitra, Anirban; Katz, Matthew H.G.; Mohile, Supriya G.; Mumber, Matthew; Schulick, Richard; Urba, Susan; Zeh, Herbert J.

In: Journal of Clinical Oncology, Vol. 35, No. 20, 10.07.2017, p. 2324-2328.

Research output: Contribution to journalReview article

Khorana, AA, Shapiro, M, Mangu, PB, Berlin, J, Engebretson, A, Hong, TS, Maitra, A, Katz, MHG, Mohile, SG, Mumber, M, Schulick, R, Urba, S & Zeh, HJ 2017, 'Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update', Journal of Clinical Oncology, vol. 35, no. 20, pp. 2324-2328. https://doi.org/10.1200/JCO.2017.72.4948
Khorana, Alok A. ; Shapiro, Marc ; Mangu, Pamela B. ; Berlin, Jordan ; Engebretson, Anitra ; Hong, Theodore S. ; Maitra, Anirban ; Katz, Matthew H.G. ; Mohile, Supriya G. ; Mumber, Matthew ; Schulick, Richard ; Urba, Susan ; Zeh, Herbert J. / Potentially curable pancreatic cancer : American society of clinical oncology clinical practice guideline update. In: Journal of Clinical Oncology. 2017 ; Vol. 35, No. 20. pp. 2324-2328.
@article{4342db1a8a98453882e99d2b5267a7d5,
title = "Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update",
abstract = "Purpose To update the Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31, 2016. The October 2016 update focuses solely on new evidence that pertains to clinical question 4 of the guideline: What is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumor? Methods The recently published results of a randomized phase III study prompted an update of this guideline. The high quality of the reported evidence and the potential for its clinical impact prompted the Expert Panel to revise one of the guideline recommendations. Results The ESPAC-4 study, a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy compared gemcitabine and capecitabine with gemcitabine monotherapy in 730 evaluable patients with resected pancreatic ductal adenocarcinoma. Median overall survival was improved in the doublet arm to 28.0 months (95{\%} CI, 23.5 to 31.5 months) versus 25.5 months (95{\%} CI, 22.7 to 27.9 months) for gemcitabine alone (hazard ratio, 0.82; 95{\%} CI, 0.68 to 0.98; P = .032). Grade 3 and 4 adverse events were similar in both arms, although higher rates of hand-foot syndrome and diarrhea occurred in patients randomly assigned to the doublet arm. Recommendations All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications. The doublet regimen of gemcitabine and capecitabine is preferred in the absence of concerns for toxicity or tolerance; alternatively, monotherapy with gemcitabine or fluorouracil plus folinic acid can be offered. Adjuvant treatment should be initiated within 8 weeks of surgical resection, assuming complete recovery. The remaining recommendations from the original 2016 ASCO guideline are unchanged.",
author = "Khorana, {Alok A.} and Marc Shapiro and Mangu, {Pamela B.} and Jordan Berlin and Anitra Engebretson and Hong, {Theodore S.} and Anirban Maitra and Katz, {Matthew H.G.} and Mohile, {Supriya G.} and Matthew Mumber and Richard Schulick and Susan Urba and Zeh, {Herbert J.}",
year = "2017",
month = "7",
day = "10",
doi = "10.1200/JCO.2017.72.4948",
language = "English (US)",
volume = "35",
pages = "2324--2328",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

TY - JOUR

T1 - Potentially curable pancreatic cancer

T2 - American society of clinical oncology clinical practice guideline update

AU - Khorana, Alok A.

AU - Shapiro, Marc

AU - Mangu, Pamela B.

AU - Berlin, Jordan

AU - Engebretson, Anitra

AU - Hong, Theodore S.

AU - Maitra, Anirban

AU - Katz, Matthew H.G.

AU - Mohile, Supriya G.

AU - Mumber, Matthew

AU - Schulick, Richard

AU - Urba, Susan

AU - Zeh, Herbert J.

PY - 2017/7/10

Y1 - 2017/7/10

N2 - Purpose To update the Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31, 2016. The October 2016 update focuses solely on new evidence that pertains to clinical question 4 of the guideline: What is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumor? Methods The recently published results of a randomized phase III study prompted an update of this guideline. The high quality of the reported evidence and the potential for its clinical impact prompted the Expert Panel to revise one of the guideline recommendations. Results The ESPAC-4 study, a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy compared gemcitabine and capecitabine with gemcitabine monotherapy in 730 evaluable patients with resected pancreatic ductal adenocarcinoma. Median overall survival was improved in the doublet arm to 28.0 months (95% CI, 23.5 to 31.5 months) versus 25.5 months (95% CI, 22.7 to 27.9 months) for gemcitabine alone (hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = .032). Grade 3 and 4 adverse events were similar in both arms, although higher rates of hand-foot syndrome and diarrhea occurred in patients randomly assigned to the doublet arm. Recommendations All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications. The doublet regimen of gemcitabine and capecitabine is preferred in the absence of concerns for toxicity or tolerance; alternatively, monotherapy with gemcitabine or fluorouracil plus folinic acid can be offered. Adjuvant treatment should be initiated within 8 weeks of surgical resection, assuming complete recovery. The remaining recommendations from the original 2016 ASCO guideline are unchanged.

AB - Purpose To update the Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31, 2016. The October 2016 update focuses solely on new evidence that pertains to clinical question 4 of the guideline: What is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumor? Methods The recently published results of a randomized phase III study prompted an update of this guideline. The high quality of the reported evidence and the potential for its clinical impact prompted the Expert Panel to revise one of the guideline recommendations. Results The ESPAC-4 study, a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy compared gemcitabine and capecitabine with gemcitabine monotherapy in 730 evaluable patients with resected pancreatic ductal adenocarcinoma. Median overall survival was improved in the doublet arm to 28.0 months (95% CI, 23.5 to 31.5 months) versus 25.5 months (95% CI, 22.7 to 27.9 months) for gemcitabine alone (hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = .032). Grade 3 and 4 adverse events were similar in both arms, although higher rates of hand-foot syndrome and diarrhea occurred in patients randomly assigned to the doublet arm. Recommendations All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications. The doublet regimen of gemcitabine and capecitabine is preferred in the absence of concerns for toxicity or tolerance; alternatively, monotherapy with gemcitabine or fluorouracil plus folinic acid can be offered. Adjuvant treatment should be initiated within 8 weeks of surgical resection, assuming complete recovery. The remaining recommendations from the original 2016 ASCO guideline are unchanged.

UR - http://www.scopus.com/inward/record.url?scp=85023616692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023616692&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.72.4948

DO - 10.1200/JCO.2017.72.4948

M3 - Review article

C2 - 28398845

AN - SCOPUS:85023616692

VL - 35

SP - 2324

EP - 2328

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 20

ER -